Not exact matches
Risk Versus Reward: The Value
of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive
new treatment including stem cell therapy, immunotherapy and
gene editing, has begun to mature, with a
handful of product approvals and others in late - stage development.
The cell therapy space, encompassing disruptive
new treatment including stem cell therapy, immunotherapy and
gene editing, has begun to mature, with a
handful of product approvals and others in late - stage development.
Before this
new study, only a
handful of genes related to baldness had been identified.
A
new gene therapy treatment has restored some sight in a
handful of blind patients suffering from Leber's congenital amaurosis, a syndrome in which, because
of a broken or missing
gene called RPE65, retinal photoreceptor cells malfunction and eventually die.
Whilst a
handful of these
genes including DOT1L, BCL2 and MEN1 are already established therapeutic targets, most
of them are novel and open up many
new possibilities for developing effective treatments against the disease.
Two
newer gene - editing methods — zinc finger nucleases, used since the late 1990s, and TALENs, first described in 2011 — allowed more precise modifications, he says, «but there was a real art and skill required, and only a
handful of labs could do those.»
The arrival
of a
new pest threat, for example, will inevitably send agronomists searching through
gene bank collections for pest - resistant seeds — often, only a
handful of seeds may have the needed trait.